Mursla Bio

11:45 AM - 12:00 PM (EDT), Wednesday, June 7, 2023 ・ Session Room 104A
- Mursla (Cambridge, UK) is an emergent techbio startup, leveraging extracellular vesicle biology to deliver nextgen multi-omics liquid biopsy tests.
- Its first product is a blood test to significantly improve the early detection of liver cancer among high risk populations so that more patients can benefit from curative treatments.
- Its test is differentiated from first generation liquid biopsy blood tests using circulating free DNA since it is tissue-specific, multi-omics and offers real time snapshot of disease biology.
- Mursla is currently running a multi-centre pilot study with four world leading universities across Europe and the support of global diagnostic leader, Roche Diagnostics.
- Mursla’s lead product is underpinned by seven patents, several publications and one of the best EV know-hows globally.
- Mursla was selected as UK Life Sciences Innovator 2023 in the Diagnostics and Precision Medicine category by UK government.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
United Kingdom
Year Founded:
Main Therapeutic Focus:
Lead Product in Development:
ExoPheno-HCC: Liver cancer surveillance blood test
Development Phase of Primary Product:
Other/Not Applicable
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Founder & CEO
Mursla Bio